Brief: Cyteir Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
16/03/2022 21:29
March 16 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYTEIR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
* Q4 LOSS PER SHARE $0.34
* PROJECTED CASH RUNWAY INTO 2024 TO SUPPORT PLANNED
RESEARCH AND
DEVELOPMENT AND CLINICAL STUDIES
* Q4 EARNINGS PER SHARE VIEW $-0.39 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw7tv86ga
Further company coverage: CYT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile